Icotrokinra(Icotrokinra) - 药物靶点：IL-23R_在研适应症：银屑病关节炎，红皮病性银屑病，泛发性脓疱型银屑病_专利_临床

概要

基本信息

药物类型

合成多肽

别名

JNJ 67864238、JNJ-2113、JNJ-4238

+ [7]

靶点

IL-23R

作用方式

抑制剂

作用机制

IL-23R抑制剂(白细胞介素23受体抑制剂)

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病其他疾病+ [2]

在研适应症

银屑病关节炎红皮病性银屑病泛发性脓疱型银屑病+ [3]

非在研适应症

克罗恩病

原研机构

Protagonist Therapeutics, Inc.

在研机构

Janssen Pharmaceutica NVJanssen Research & Development LLC

强生（中国）投资有限公司

+ [2]

非在研机构

Protagonist Therapeutics, Inc.

权益机构

Protagonist Therapeutics, Inc.

Janssen Biotech, Inc.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 1311911322

来源: *****

关联

28

项与 Icotrokinra 相关的临床试验

CTRI/2025/04/084956

/ Not yet recruiting临床3期

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis - ICONIC-PsA 2

开始日期2025-05-16

申办/合作机构-

ISRCTN56487896

/ Recruiting临床3期

A phase III multicenter, randomized, double-blind, placebo-controlled and ustekinumab active comparator-controlled study to evaluate the efficacy and safety of JNJ-77242113 for the treatment of participants with moderate to severe plaque psoriasis

开始日期2025-05-09

申办/合作机构

Janssen-Cilag International NV

CTRI/2025/04/084370

/ Not yet recruiting临床3期

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-na ve Participants with Active Psoriatic Arthritis - ICONIC-PsA 1

开始日期2025-05-08

申办/合作机构-

100 项与 Icotrokinra 相关的临床结果

登录后查看更多信息

100 项与 Icotrokinra 相关的转化医学

登录后查看更多信息

100 项与 Icotrokinra 相关的专利（医药）

登录后查看更多信息

4

项与 Icotrokinra 相关的文献（医药）

2025-03-01·JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis

Article

作者: Ferris, Laura K ; Iaconangelo, Charles ; Tyring, Stephen K ; Huang, Yu-Huei ; Shen, Yaung-Kaung ; Ota, Takayuki ; Bissonnette, Robert ; Pink, Andrew E ; Bagel, Jerry ; Kokolakis, Georgios ; Li, Shu ; DeLozier, Amy M

BACKGROUND:

More patients with moderate-to-severe plaque psoriasis achieved responses with JNJ-77242113, a targeted oral peptide inhibiting interleukin-23 receptor signaling, versus placebo (PBO) at week (W)16 of the phase 2 FRONTIER-1 study.

OBJECTIVE:

FRONTIER-2, a long-term extension of FRONTIER-1, evaluated JNJ-77242113 through 1 year.

METHODS:

FRONTIER-1 participants received JNJ-77242113 at doses from 25 mg daily to 100 mg twice daily or PBO through W16. Patients completing FRONTIER-1 could enroll in FRONTIER-2 and continue JNJ-77242113 at the same dose through W52. Those on PBO crossed over to JNJ-77242113 100 mg daily for W16-52. Safety follow-up continued through W56.

RESULTS:

Most (89%) FRONTIER-1 patients continued to FRONTIER-2. Across outcomes, response rates were maintained from W16-52. The highest response rates generally occurred with JNJ-77242113 100 mg twice daily. At W52, 76% of patients achieved up to 75% improvement in Psoriasis Area and Severity Index (PASI75) with 100 mg twice daily; rates of clear or almost clear skin were 64% (PASI90), 74% (Investigator's Global Assessment 0/1), 40% (PASI100), and 43% (Investigator's Global Assessment 0). From W16-56, 59% of JNJ-77242113-treated patients had ≥1 adverse events. Serious adverse events, considered unrelated to treatment by investigators, occurred in 4% of patients.

LIMITATIONS:

The study was limited by the small number of patients in each treatment group and the descriptive nature of the longer-term data.

CONCLUSION:

Rates of skin clearance with JNJ-77242113 were durable to 1 year and no safety signals were identified.

2025-02-01·The Journal of clinical and aesthetic dermatology

From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments.

Review

作者: Merola, Joseph F ; Gottlieb, Alice B ; Romanelli, Sarah ; Childs, Beth

Psoriasis (PsO) is an immune-mediated, chronic inflammatory skin disease that significantly impairs quality of life. Its treatment landscape is rapidly evolving, providing better disease control. Here, we highlight updates in biologics, obtaining coverage for biologics under Medicare, the PsO-to-psoriatic arthritis (PsA) transition, and orally administered drugs, as presented at the 2024 Masterclass in Dermatology in Puerto Rico. We provide a concise overview of the evolving therapeutic landscape and its impact on personalized care for patients with PsO. The toolkit of biologics is expanding, with agents that target interleukin (IL)-17 and IL-23 pathways addressing symptoms across multiple disease domains. Interchangeable biosimilars reduce financial barriers to access, particularly for tumor necrosis factor (TNF) inhibitors. An IL-36 receptor antibody, spesolimab, demonstrates efficacy in generalized pustular psoriasis. Further, Medicare has expanded coverage of certain biologics, addressing challenges to treating patients of this population. PsA is an important comorbidity that can significantly reduce quality of life. Recent studies suggest that biologic therapies-including TNF inhibitors, as well as anti-IL-17, anti-IL-23, and anti-IL-12/23 agents-protect against arthritis onset in PsO patients. In addition to traditional modes of delivery, novel formulations address widespread preference for orally administered therapies. Deucravacitinib, a tyrosine kinase (TYK) 2 inhibitor, is highly selective, effective, and safe. Additionally, JNJ-77242113, an investigational IL-23 receptor antagonist, constitutes an orally administered, targeted biologic therapy. Together, these developments are shaping the future for patients with PsO. It is our goal to simplify the complexities of emerging treatment options, offering clinicians a concise and useful guide for patient management.

2024-02-08·The New England journal of medicine1区 · 医学

An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis

1区 · 医学

Article

作者: Ferris, Laura K ; Li, Shu ; Bissonnette, Robert ; Papp, Kim ; Kannan, Arun ; Shen, Yaung-Kaung ; Pinter, Andreas ; Vender, Ronald ; Miller, Megan ; Gerdes, Sascha ; Rich, Phoebe ; DeKlotz, Cynthia

BACKGROUND:

The use of monoclonal antibodies has changed the treatment of several immune-mediated inflammatory diseases, including psoriasis. However, these large proteins must be administered by injection. JNJ-77242113 is a novel, orally administered interleukin-23-receptor antagonist peptide that selectively blocks interleukin-23 signaling and downstream cytokine production.

METHODS:

In this phase 2 dose-finding trial, we randomly assigned patients with moderate-to-severe plaque psoriasis to receive JNJ-77242113 at a dose of 25 mg once daily, 25 mg twice daily, 50 mg once daily, 100 mg once daily, or 100 mg twice daily or placebo for 16 weeks. The primary end point was a reduction from baseline of at least 75% in the Psoriasis Area and Severity Index (PASI) score (PASI 75 response; PASI scores range from 0 to 72, with higher scores indicating greater extent or severity of psoriasis) at week 16.

RESULTS:

A total of 255 patients underwent randomization. The mean PASI score at baseline was 19.1. The mean duration of psoriasis was 18.2 years, and 78% of the patients across all the trial groups had previously received systemic treatments. At week 16, the percentages of patients with a PASI 75 response were higher among those in the JNJ-77242113 groups (37%, 51%, 58%, 65%, and 79% in the 25-mg once-daily, 25-mg twice-daily, 50-mg once-daily, 100-mg once-daily, and 100-mg twice-daily groups, respectively) than among those in the placebo group (9%), a finding that showed a significant dose-response relationship (P<0.001). The most common adverse events included coronavirus disease 2019 (in 12% of the patients in the placebo group and in 11% of those across the JNJ-77242113 dose groups) and nasopharyngitis (in 5% and 7%, respectively). The percentages of patients who had at least one adverse event were similar in the combined JNJ-77242113 dose group (52%) and the placebo group (51%). There was no evidence of a dose-related increase in adverse events across the JNJ-77242113 dose groups.

CONCLUSIONS:

After 16 weeks of once- or twice-daily oral administration, treatment with the interleukin-23-receptor antagonist peptide JNJ-77242113 showed greater efficacy than placebo in patients with moderate-to-severe plaque psoriasis. (Funded by Janssen Research and Development; FRONTIER 1 ClinicalTrials.gov number, NCT05223868.).

202

项与 Icotrokinra 相关的新闻（医药）

2025-05-22

·生物制品圈

强生亮出底牌

强生频繁亮出新王牌，按下了自免王座争夺战的加速键。4月30日，强生的FcRn阻断剂Nipocalimab（尼卡利单抗）获FDA批准上市，用于治疗全身型重症肌无力（gMG）患者，将成为强生争夺“自免一哥”宝座的利器。毕竟，尼卡利单抗是强生以65亿美元收购Momenta而获得，商业价值可见一斑。而且，Argenx/再鼎医药的艾加莫德α（Efgartigimod），2025年第一季度实现销售额7.9亿美元，同比大幅增长99%，充分验证了FcRn赛道潜力。更何况，强生在自免领域不只有这一张王牌。近期，强生在皮肤病研究学会（SID）年会上公布了口服IL-23R多肽拮抗剂icotrokinra（JNJ-2113）的最新III期临床试验数据，研究结果令人振奋，有望为银屑病患者提供一种创新的口服治疗方案。显然，“自免一哥”这个名号，强生是志在必得。TONACEA01新王牌登场艾加莫德用近乎翻倍的增速，给FcRn靶向药物带来了巨大的想象空间。艾加莫德是全球首款获批的FcRn拮抗剂，目前已斩获3项适应症，包括全身型重症肌无力（gMG）、原发性免疫性血小板减少症（ITP）、慢性炎症性脱髓鞘性多发性神经病（CIDP）。从销售表现看，艾加莫德保持着强劲的销售态势：2023年跻身“重磅炸弹”药物行列，2024年全球销售额同比增长83%至22亿美元，今年一季度同比增长99%至7.9亿美元。此外，Argenx还在针对艾加莫德拓展更广泛的适应症，目前正在15种严重自身免疫性疾病中接受评估，包括持续性多发性硬化症、特发性血小板减少性紫癜等。根据ODDO BHF分析师预测，艾加莫德将在2035年达到110亿美元的销售峰值。另一款FcRn拮抗剂——优时比的罗泽利昔珠单抗（Rozanolixizumab），在2023年6月获FDA批准上市，用于抗乙酰胆碱受体（AChR）或抗肌肉特异性酪氨酸激酶（MuSK）抗体阳性的gMG患者，也取得了不错的商业化表现：销售额从2023年的1900万欧元快速飙升至2024年的2.02亿欧元（约2.27亿美元）。此外，罗泽利昔珠单抗也显示出广谱潜力，在全球已开展针对多种自身免疫性疾病的21项临床试验。图片来源：开元证券研报不同于上述两种FcRn拮抗剂，强生的尼卡利单抗是一种FcRn阻断剂，可通过特异性结合FcRn，阻断其与IgG抗体的结合，减少IgG抗体的回收和循环，从根本上降低血液中自身抗体水平。4月30日，尼卡利单抗获得FDA批准上市，用于治疗全身型重症肌无力（gMG）患者，成为首个也是唯一一个获批用于治疗抗AChR抗体和抗MuSK抗体阳性成人及12岁及以上儿童gMG患者的FcRn阻断剂。据统计，全球约有70万例重症肌无力（MG）患者，其中约85%的患者会发展成为gMG。从给药方式看，艾加莫德已获批静脉注射和皮下注射两种剂型，而强生直接推出尼卡利单抗皮下注射剂型（30-90秒内完成给药），相比于静脉注射（通常需要约1小时），可大大提高给药的便捷性和患者的依从性。另外，强生还在拓展尼卡利单抗用于治疗多种适应症，包括类风湿关节炎、干燥综合征、系统性红斑狼疮、慢性炎症性脱髓鞘性多发性神经病（CIDP）、温抗体型自身免疫性溶血性贫血（wAIHA）、胎儿和新生儿溶血病 (HDFN）等。强生预计尼卡利单抗的销售峰值将达到50亿美元。值得注意的是，尼卡利单抗只是强生为争夺“自免一哥”打出的其中一张王牌。TONACEA02争夺“一哥”宝座自免江湖风云突变。尽管艾伯维牢牢占据“自免一哥”宝座，但强生一直在奋起直追，打造了多款自免产品，包括Stelara（乌司奴单抗）、Tremfya（古塞奇尤单抗）、Simponi（戈利木单抗）、Remicade（英夫利昔单抗），2024年销售额分别达到103.61亿美元、36.7亿美元、21.9亿美元、16.05亿美元。对比来看，2024年艾伯维的自免业务凭借266.82亿美元收入位居全球制药巨头榜首，而强生的自免业务收入达178.28亿美元，位居第二，双方差距达到88.54亿美元，这几乎相当于Humira（阿达木单抗）的营收（2024年销售额为89.93亿美元）。不过，强生自免业务正处于新老产品交接期，短期内想拿下“自免一哥”宝座，存在一定的挑战。这主要是由于，强生的核心大单品Stelara面临专利到期问题，受到生物类似药的冲击，导致2024年收入同比下降4.6%，2025年第一季度销售额更是同比下滑34%至16.3亿美元；而且，其他重磅产品英夫利西单抗、戈利木单抗也面临衰退的困境，2024年分别同比下降12.8%、-0.3%。目前，已展现出接棒之势、能扛起自免领域重任的是iL-23抑制剂Tremfya。得益于持续拓展适应症，Tremfya正处于快速放量期，2024年收入同比增长16.6%，2025年Q1实现销售额同比增长18.2%至9.56亿美元，成为自免领域的新支柱。图片来源：方正证券研报相较之下，尽管艾伯维的核心大单品修美乐已退位全球自免“药王”宝座，但“接棒人”林立，IL-23单抗Skyrizi（利生奇珠单抗）、JAK1抑制剂Rinvoq（乌帕替尼），2024年分别实现销售额高达117.18亿美元、59.71亿美元，同比增长50.9%、50.4%。此外，艾伯维还在不断提升竞争优势，在2024年达成了7笔自免相关的并购及BD交易，包括收购Nimble、Landos Biopharma，拿下一系列口服多肽类药物、潜在“first-in-class”口服NLRX1激动剂NX-13，以及斥资超17亿美元引进明济生物一款处于临床前开发阶段的用于治疗炎症性肠病（IBD）的下一代TL1A抗体FG-M701。强生不甘落后，除了在2020年斥资65亿美元收购尼卡利单抗，还在2024年不断加码自免赛道：5月，先是以8.5亿美元收购Proteologix，获得治疗特应性皮炎和哮喘的IL-13/TSLP双抗PX128、治疗特应性皮炎的IL-13/IL-22双抗PX130，接着以12.5亿美元收购Numab的全资子公司Yellow Jersey Therapeutics，获得针对特应性皮炎的IL-4R/IL-31双抗NM26；12月，以12.5亿美元引进日本药企Kaken Pharmaceutical一款临床前阶段的STAT6抑制剂KP-723除日本外的全球权益。可见，强生布局了一系列差异化的自免产品组合，尤其是从Protagonist引进的口服IL-23R多肽拮抗剂JNJ-2113，峰值销售额或达50亿美元，为强生争夺“自免一哥”增添了重要筹码。TONACEA03下一张王牌浮出水面一直以来，自免治疗药物不断迭代更新。到如今，MNC巨头开始陆续入局口服自免药，强生自然也不例外。2017年，强生旗下杨森制药斥资近10亿美元与Protagonist Therapeutics签订独家许可合作协议，共同开发口服IL-23R多肽拮抗剂JNJ-2113（Icotrokinra，前称PN-235）。目前，Icotrokinra治疗斑块状银屑病的III期ICONIC-LEAD研究已获得了积极的关键结果，成为首款完成III期研究的口服IL-23R靶向药物，预计2025年提交上市申请。近期，强生在皮肤病研究学会（SID）年会上公布了Icotrokinra的最新III期临床关键数据，研究结果显示：Icotrokinra不仅总体疗效显著，更在改善包括头皮、生殖器、手足等传统“治疗难点”部位的皮损方面表现出色，有望为银屑病患者提供一种创新的口服治疗方案。值得一提的是，强生还启动了icotrokinra头对头自家核心大单品Stelara的III期ICONIC-ASCEND试验，以求实现自我迭代升级。而且，icotrokinrah治疗溃疡性结肠炎疾病的IIb期ANTHEM-UC研究达到了主要终点，展现出广谱潜力。图片来源：财通证券研报除强生外，布局口服自免药的MNC巨头，还包括艾伯维、赛诺菲、武田制药、礼来等。2020年，赛诺菲以20亿美元与Kymera达成合作，共同开发用于治疗免疫炎症疾病的PROTAC降解剂KT-474，之后双方再度牵手，扩大KT-474治疗化脓性汗腺炎、特应性皮炎两项Ⅱ期临床试验；2022年，武田制药豪掷60亿美元收购Nimbus Lakshmi，将治疗银屑病和IBD疾病的口服TYK2抑制剂Zasocitinib（TAK-279）纳入囊中。自免口服药之所以能吸引MNC巨头抢滩入局，是因为具备多种优势，包括有效性（快速起效）、安全性（副作用可控）、顺应性（用药便捷，依从性高）、经济性（成本优势显著）。基于上述种种因素，强生预测icotrokinrah的峰值销售额能突破50亿美元。这无疑为强生争夺“自免一哥”提供了莫大助力。— 结语 —可见，强生在自免领域撒下的“天罗地网”已悄然收拢，与艾伯维的“自免一哥”之争进入了白热化阶段。这场对决的胜负手，早已不是单一产品的较量，而是“广度+深度”兼备的产品矩阵。当然，从更高层面来看，两大巨头的“系统性作战”能力，或将重新定义自免疾病的治疗标准。参考资料：1.各家公司的财报、公告、官微2.《刚刚！强生超440亿元押注的重磅单抗获FDA批准上市》，Insight数据库，2025年05月01日3.《口服自免！又一个医药爆点正在崛起》，博药，2025年04月03日4.开元证券、方正证券、财通证券研报识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

上市批准临床3期并购

2025-05-12

·PMLiVE

J&J/Protagonist’s icotrokinra shows promise in difficult-to-treat plaque psoriasis

Johnson & Johnson (J&J) and Protagonist Therapeutics’ investigational oral peptide icotrokinra (JNJ-2113) has been associated with significant skin clearance in patients with difficult-to-treat psoriasis, according to new data from a late-stage study of the candidate. The phase 3 ICONIC-TOTAL trial has been evaluating the drug in adults and adolescents aged 12 years and older with at least moderate plaque psoriasis affecting high-impact skin sites. It is estimated that eight million people in the US are living with plaque psoriasis, which causes inflamed, scaly plaques that may be itchy or painful. Almost 25% of patients are affected by moderate-to-severe cases of the immune-mediated skin disease and, while the condition can occur anywhere on the body, psoriasis on highly visible areas or sensitive skin can have an increased negative impact on quality of life. Results presented at this year’s Society for Investigative Dermatology annual meeting demonstrated that 57% of patients treated with once-daily icotrokinra achieved the study’s primary endpoint of an Investigator’s Global Assessment (IGA) score of zero or one (clear or almost clear skin) and at least a two-grade improvement from baseline at week 16, compared to 6% of patients randomised to receive placebo. Among patients with scalp psoriasis, 66% achieved a scalp-specific IGA score of zero or one compared to 11% receiving placebo at week 16, while 77% of icotrokinra-treated genital psoriasis patients achieved a static Physician’s Global Assessment of Genitalia score of zero or one versus 21% of those in the placebo cohort at the same time point. A higher rate of skin clearance was also seen in a smaller subset of patients with hand/foot psoriasis, with 42% of those in the icotrokinra group achieving a hand and/or foot Physician’s Global Assessment score of zero or one compared to 26% receiving placebo at week 16. Study investigator, Melinda Gooderham, said: “Results from the ICONIC-TOTAL study demonstrate impressive rates of skin clearance in these difficult-to-treat areas and show the potential for treatment with icotrokinra to offer patients a novel therapeutic option that aligns with their treatment needs and preferences.” Icotrokinra was jointly discovered and is being developed under a licence and collaboration agreement between J&J and Protagonist. Under the terms of the deal, J&J has exclusive global rights to develop the candidate in mid-stage studies and beyond, as well as to commercialise compounds derived from the research conducted in accordance with the agreement against multiple indications.

临床结果临床3期引进/卖出ASCO会议

2025-05-10

·ETPharma

J&J's oral psoriasis drug helps patients achieve clear skin in late-stage study

Bengaluru: Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study, as the once-daily pill helped patients achieve clear or almost clear skin. The drugmaker has been working on more convenient treatment options as its injectable psoriasis drug Stelara, which gained over $10 billion in sales last year, faces stiff competition from cheaper rivals. J&J said last month it expects the drug, icotrokinra , to generate sales of $700 million in 2028. BTIG analyst Julian Harrison expects icotrokinra to "complement rather than disrupt" market leaders, including J&J's Tremfya and AbbVie's Skyrizi. Icotrokinra helped 66 per cent of patients with scalp psoriasis and 77 per cent of those with genital psoriasis achieve significantly clear skin compared to 11 per cent and 21 per cent success rate in patients on placebo, respectively, J&J said. The drug was administered to patients 12 years and older with at least moderate plaque psoriasis affecting "high-impact" areas, including the scalp and genitals, for 16 weeks. Plaque psoriasis, an immune-mediated condition characterized by thick, scaly patches or plaques, is the most common type of psoriasis. Psoriasis is estimated to affect more than 7.5 million adults in the United States. The study enrolled 311 patients, who were randomly chosen to receive either icotrokinra or placebo for a period of 16 weeks. J&J is developing the drug with partner Protagonist Therapeutics. Icotrokinra is designed to block a protein, IL-23, involved in inflammatory responses and is being tested as a potential treatment for other inflammatory conditions, such as ulcerative colitis. In a separate late-stage study last year, the drug showed significant skin clearance in patients with moderate-to-severe plaque psoriasis. (Reporting by Mariam Sunny and Padmanabhan Ananthan in Bengaluru; Editing by Vijay Kishore and Shinjini Ganguli)

临床结果上市批准

100 项与 Icotrokinra 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
银屑病关节炎	临床3期	美国	Janssen Research & Development LLC	2025-01-09
银屑病关节炎	临床3期	中国	Janssen Research & Development LLC	2025-01-09
银屑病关节炎	临床3期	日本	Janssen Research & Development LLC	2025-01-09
银屑病关节炎	临床3期	阿根廷	Janssen Research & Development LLC	2025-01-09
银屑病关节炎	临床3期	澳大利亚	Janssen Research & Development LLC	2025-01-09
银屑病关节炎	临床3期	巴西	Janssen Research & Development LLC	2025-01-09
银屑病关节炎	临床3期	保加利亚	Janssen Research & Development LLC	2025-01-09
银屑病关节炎	临床3期	加拿大	Janssen Research & Development LLC	2025-01-09
银屑病关节炎	临床3期	捷克	Janssen Research & Development LLC	2025-01-09
银屑病关节炎	临床3期	丹麦	Janssen Research & Development LLC	2025-01-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06095115 (ICONIC-LEAD, PipelineReview) 人工标引	临床3期	斑块状银屑病	-	Icotrokinra	夢餘構積膚製構鑰選窪(製鏇夢廠窪艱觸醖鏇網) = 鏇簾夢廠醖顧襯窪鑰選醖醖齋窪積廠餘衊憲糧 (窪廠齋繭淵夢夢廠獵鬱 ) 更多	积极	2025-04-10
				Placebo	夢餘構積膚製構鑰選窪(製鏇夢廠窪艱觸醖鏇網) = 鹽鹹積糧繭襯鏇齋鹽觸醖醖齋窪積廠餘衊憲糧 (窪廠齋繭淵夢夢廠獵鬱 ) 更多
NCT06049017 (ANTHEM-UC, NEWS) 人工标引	临床2期	溃疡性结肠炎	252	Icotrokinra	觸積鏇遞夢鹽構顧鹹構(鑰餘積鏇構築選夢遞廠) = 憲醖糧顧獵窪鏇鑰遞憲鹽遞觸醖鹹蓋廠窪遞廠 (淵繭積襯壓選憲憲範襯 ) 达到更多	积极	2025-03-10
				Placebo	觸積鏇遞夢鹽構顧鹹構(鑰餘積鏇構築選夢遞廠) = 構獵壓鏇醖廠廠齋膚遞鹽遞觸醖鹹蓋廠窪遞廠 (淵繭積襯壓選憲憲範襯 ) 达到更多
NCT06095115 (ICONIC-LEAD, NEWS 1 \| NEWS 2) 人工标引	临床3期	斑块状银屑病	-	JNJ-77242113	願醖齋顧襯遞獵網願餘(夢築淵淵願憲鹽齋膚積) = 襯範糧鬱蓋觸顧鑰選餘齋鹹願淵糧窪艱築窪繭 (獵憲鏇襯築鹽淵糧範糧 ) 达到更多	积极	2024-11-18
				Placebo	願醖齋顧襯遞獵網願餘(夢築淵淵願憲鹽齋膚積) = 壓襯糧鏇願選衊網醖廠齋鹹願淵糧窪艱築窪繭 (獵憲鏇襯築鹽淵糧範糧 ) 达到更多
NCT06095102 (ICONIC-TOTAL, Company_Website) 人工标引	临床3期	斑块状银屑病	-	Icotrokinra	憲醖壓遞壓齋鹹顧窪壓(範選構網憲糧餘鑰鏇觸) = positive topline results from the Phase 3 ICONIC-TOTAL study showed once-daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo. 構網構鬱艱鏇壓蓋蓋遞 (餘廠願願鹹獵淵窪醖蓋 ) 达到	积极	2024-11-18
				Placebo
NCT05364554 (FRONTIER 2, PRNewswire) 人工标引	临床2期	斑块状银屑病	227	JNJ-2113	構獵鏇夢選艱艱蓋繭積(襯淵糧觸衊襯繭醖鏇築) = 範顧築範襯鏇衊獵築衊選選築艱醖蓋繭鹽製鹽 (構壓蓋夢選醖鏇繭蓋鏇 ) 更多	积极	2024-03-09
NCT05223868 (FRONTIER 1, Literature) 人工标引	临床2期	斑块状银屑病	255	JNJ-77242113 25 mg once daily	製遞獵醖觸網築獵襯鏇(築艱鑰壓艱簾鏇製顧網) = 鹹獵齋艱遞範壓壓簾齋淵壓簾築壓簾淵簾獵淵 (鹹糧範膚選鹹鹹廠獵夢 ) 达到	积极	2024-02-08
				JNJ-77242113 25 mg twice daily	製遞獵醖觸網築獵襯鏇(築艱鑰壓艱簾鏇製顧網) = 願膚獵齋憲餘鹽淵繭襯淵壓簾築壓簾淵簾獵淵 (鹹糧範膚選鹹鹹廠獵夢 ) 达到
NCT05223868 (Pubmed \| N Engl J Med)	临床2期	斑块状银屑病	-	JNJ-77242113 25mg once daily	餘繭襯範範蓋艱遞觸壓(醖壓齋鹹遞衊願遞鏇襯) = similar in the combined JNJ-77242113 dose group (52%) and the placebo group (51%) 鑰觸遞衊築範窪簾醖窪 (壓憲窪繭餘觸廠蓋鹽構 ) 更多	-	2024-02-08
				JNJ-77242113 25mg twice daily
NCT05223868 (FRONTIER 1, WCD 12023 \| WCD 22023) 人工标引	临床2期	斑块状银屑病	255	JNJ-77242113 25 mg daily	獵顧築積醖艱簾襯窪醖(繭壓遞製遞顧鏇膚壓廠) = 願淵壓網窪築衊壓範餘淵糧鬱選夢襯衊餘選積 (範遞醖壓鏇製構願範觸 ) 达到更多	积极	2023-07-04
				JNJ-77242113 25 mg twice daily	獵顧築積醖艱簾襯窪醖(繭壓遞製遞顧鏇膚壓廠) = 構鑰衊淵願憲遞獵齋構淵糧鬱選夢襯衊餘選積 (範遞醖壓鏇製構願範觸 ) 达到更多
NCT04102111 (PRISM, CTgov)	临床2期	克罗恩病	48	Placebo (Placebo)	襯齋範憲觸壓鏇蓋糧積(夢觸鏇鑰鏇獵鬱鏇積網) = 鬱構齋淵醖鏇艱獵遞簾鑰鹽繭鑰網廠衊遞顧艱 (窪觸觸壓艱願簾膚製觸, 94.71) 更多	-	2022-12-09
				JNJ-67864238 (JNJ-67864238)	襯齋範憲觸壓鏇蓋糧積(夢觸鏇鑰鏇獵鬱鏇積網) = 餘淵蓋築鑰鏇顧顧襯繭鑰鹽繭鑰網廠衊遞顧艱 (窪觸觸壓艱願簾膚製觸, 124.94) 更多
UEGW2019	N/A	-	-	PTG-200 150 mg QD	衊醖醖襯獵積糧憲築獵(艱淵顧網鹹觸蓋淵鹹鏇) = 窪鹹齋膚淵醖獵齋選簾遞衊積築顧願鹽餘窪憲 (襯範蓋鏇鹹鏇艱餘襯積, 0.81) 更多	-	2019-10-01
				PTG-200 300 mg QD	衊醖醖襯獵積糧憲築獵(艱淵顧網鹹觸蓋淵鹹鏇) = 鬱憲網襯窪構鑰蓋鏇憲遞衊積築顧願鹽餘窪憲 (襯範蓋鏇鹹鏇艱餘襯積, 1.23) 更多